Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced...

Area of Science:

• Oncology
• Immunotherapy

Background:

• Triple-negative breast cancer (TNBC) presents the poorest prognosis among breast cancer subtypes.
• TNBC exhibits significant immunogenicity, suggesting potential therapeutic benefit from immune checkpoint inhibitors.

Purpose of the Study:

• To review and synthesize findings from clinical studies involving PD-1/PD-L1 inhibitors in advanced TNBC.
• To explore strategies for optimizing the use of PD-1/PD-L1 inhibitors and identifying patient subgroups who may benefit most.

Main Methods:

• Systematic review of published clinical trials.
• Analysis of studies utilizing PD-1/PD-L1 inhibitors for advanced TNBC treatment.

Main Results:

• PD-1/PD-L1 inhibitors are being investigated for their potential to improve TNBC outcomes.
• Current data highlight ongoing research into maximizing the efficacy of these immunotherapies.
• Patient selection criteria and optimal treatment regimens are areas of active clinical debate.

Conclusions:

• Further research is needed to establish definitive guidelines for PD-1/PD-L1 inhibitor therapy in advanced TNBC.
• Identifying predictive biomarkers and refining treatment strategies are crucial for improving patient prognosis.